# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomb...
Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite co...
Piper Sandler analyst Christopher Raymond maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $1...
TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both r...